Clinical Trial

Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 18, 2025 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, randomized, double-blind, placebo-controlled Phase II/III seamless clinical study evaluating the efficacy, safety, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, and immunogenicity of MG-K10 humanized monoclonal antibody injection in the treatment of seasonal allergic rhinitis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-04-15
Trial Details
NCT Number NCT06846385
Lead Sponsor Shanghai Mabgeek Biotech.Co.Ltd
Conditions Seasonal Allergic Rhinitis
Enrollment 160 participants
Start Date 2025-03-20
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-18